

# Symbiox Investment & Trading Co Ltd

7A, Rani Rashmoni Road  
Kolkata - 700 013  
Phone : 033-3251 5833  
CIN : L65993WB1979PLC032012  
Website : www.symbioxinvestment.com  
E-mail ID : symbioxinvestment100@gmail.com

Date: 30<sup>th</sup> May, 2019

To,  
Compliance Department  
Metropolitan Stock Exchange of India Limited  
Vibgyor Towers, 4th floor, Plot No C 62, G - Block  
Opp. Trident Hotel, Bandra Kurla Complex,  
Bandra (E),  
Mumbai - 400 098

To,  
The Calcutta Stock Exchange Limited  
7, Lyons Range,  
Kolkata- 700 001

To,  
The Bombay Stock Exchange Limited,  
PJ Towers, Dalal Street  
Mumbai- 400 001

**Sub: Audited Financial results for the quarter and year ended 31.03.2019**  
BSE Scrip Code: 539278 CSE Scrip Code: 029461 Symbol: SYMBIOX

Dear Sir,

This is to inform you that Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirement) Regulation 2015, the Board of Directors of the company at their meeting held on 30<sup>th</sup> May, 2019, have approved the Audited Financial Results of the company for the quarter and year ended 31<sup>st</sup> March, 2019.

1. Approved the Audited Financial Results (Standalone) for the Quarter and Year ended on 31<sup>st</sup> March, 2019 as recommended by the Audit committee.
2. Auditor's Report in the prescribed format issued by the Statutory Auditor of the Company also attached herewith
3. Declaration for unmodified audit report in respect of Standalone financial statements for the year 2018-2019 under SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015

Kindly note that the meeting of the Board of Directors commenced at 03.00 P.M and concluded at 04:45 P.M

Please take the same on your record and acknowledge the receipt of the same.

Thanking You.

Yours Faithfully,

For Symbiox Investment & Trading Co Ltd

*Neha Pansari*

Neha Pansari  
Company Secretary  
M no: A31763





**PODDAR AGARWAL & CO.**

Chartered Accountants

ADDRESS : RGM, 8/79 ASWINI NAGAR  
2ND FLOOR, BEHIND CALCUTTA PUBLIC SCHOOL  
Joramandir, KOLKATA - 700 059  
CONTACT : 9883760030/9331926937  
EMAIL : poddaragarwalandco@gmail.com


**Auditor, Report on Quarterly Standalone Financial Result and Year to date Standalone Financial Results of Symbiox Investment & Trading Co Ltd pursuant to the Regulation 33 of the SEBI ( Listing Obligation and Disclosure Requirements) Regulations, 2015.**

The Board of Directors,  
**Symbiox Investment & Trading Co Ltd**  
7A, Rani Rashmoni Road  
Kolkata- 700 013

1. We have audited the accompanying statements of Standalone Financial Results of **Symbiox Investment & Trading Co Ltd** ("the Company") for the quarter ended 31<sup>st</sup> March, 2019 and for the year ended March 31, 2019, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI ( Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI circular bearing nos. CIR/CFD/FAC/62/2016 dated July 5, 2016 in this regard. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the related financial statements which are in accordance with the Accounting Standards prescribed under section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institution of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involved performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The Procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



BRANCH OFFICE, ASANSOL



**PODDAR AGARWAL & CO.**

Chartered Accountants

ADDRESS : RGM, 8/79 ASWINI NAGAR  
2ND FLOOR, BEHIND CALCUTTA PUBLIC SCHOOL  
Joramandir, KOLKATA - 700 059  
CONTACT : 9883760030/9331926937  
EMAIL : poddaragarwalandco@gmail.com

3. In our opinion and to best of information and according to the explanations given to us, the statement:

- i. Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI circular bearing nos. CIR/CFD/FAC/62/2016 dated July 5, 2016 in this regard.
- ii. Gives a true and fair view in conformity with the aforesaid accounting standards and other accounting principles generally accepted in India of the net profit for the quarter ended March 31, 2019 as well as for the year ended on that date.

**For Poddar Agarwal & Co.**

Chartered Accountants

ICAI Firm Registration: 329486E

Pravin Poddar

Partner

Membership Number: 300906

Place of Signature: Kolkata

Date: 30/05/2019



BRANCH OFFICE : ASANSOL

# Symbiox Investment & Trading Co Ltd

7A, Rani Rashmoni Road  
Kolkata - 700 013  
Phone : 033-3251 5833  
CIN : L65993WB1979PLC032012  
Website : www.symbioxinvestment.com  
E-mail ID : symbioxinvestment100@gmail.com

## Statement of Audited Financial Result for the year ended 31st March, 2019

(Rupees in Lakh except EPS)

	Particulars	Quarter ended			Year ended	
		31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue From Operations	89.72	0.00	142.50	89.72	185.51
II	Other Income	49.47	7.55	42.07	85.24	104.02
III	Total Income (I+II)	<b>139.19</b>	<b>7.55</b>	<b>184.57</b>	<b>174.96</b>	<b>289.53</b>
IV	<b>EXPENSES</b>					
	Cost of materials consumed	-	-	-	-	-
	Purchases of Stock-in-Trade	143.75	0.00	187.50	143.75	235.14
	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	6.82	2.27	3.34	15.06	11.43
	Finance costs	-	-	-	-	-
	Depreciation and amortization expense	0.00	0.00	0.06	0.00	0.37
	Other expenses	3.48	1.71	1.70	12.49	24.86
	Total expenses (IV)	<b>154.05</b>	<b>3.98</b>	<b>192.60</b>	<b>171.30</b>	<b>271.80</b>
V	Profit/(loss) before exceptional items and tax (I- IV)	-14.86	3.57	-8.03	3.66	17.73
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(loss) before tax (V-VI)	-14.86	3.57	-8.03	3.66	17.73
VIII	Tax expense:					
	(1) Current tax	-3.79	0.92	3.35	0.98	4.57
	(2) Deferred tax	-	-	-	-	-
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-11.07	2.65	-4.68	2.68	13.16
X	Profit/(loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-11.07	2.65	-4.68	2.68	13.16
XIII	Profit/(loss) for the period (IX+XII)	-11.07	2.65	-4.68	2.68	13.16
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-



	B (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)					
XVI	Earnings per equity share (for continuing operation):					
	(1) Basic	-0.035	0.0085	-0.015	0.009	0.042
	(2) Diluted	-0.035	0.0085	-0.015	0.009	0.042
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000
XVIII	Earnings per equity share (for discontinued & continuing operations)					
	(1) Basic	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000

**Note:**

1	The above Audited financial results were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 30th May, 2019
2	The previous period figures have been regrouped wherever necessary.
3	The Statutory auditors of the Company have carried out a "Auditor's report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.
4	The Company has adopted Indian Accounting standards (Ind AS) with effect from 01 <sup>st</sup> April, 2017 and accordingly, the above results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013
5	The above results for the quarter & year ended 31st March, 2019 along with Auditor Report has been approved by the Board of Directors of the Company.

For and behalf of Board SYMBIOX INVESTMENT & TRADING CO LTD

Place: Kolkata  
Date: 30.05.2019



*Neha Pansari*  
Neha Pansari  
Company secretary  
M No: A31763


# Symbiox Investment & Trading Co Ltd

7A, Rani Rashmoni Road  
Kolkata - 700 013  
Phone : 033-3251 5833  
CIN : L65993WB1979PLC032012  
Website : www.symbioxinvestment.com  
E-mail ID : symbioxinvestment100@gmail.com

## Statement of Assets and Liabilities for Company

(Rs, in Lakh)

Standalone Statement of Assets and Liabilities		As at 31st March 2019	As at 31st March, 2018
Particulars		(Audited)	(Audited)
<b>A</b>	<b>ASSEST</b>		
1	<b>Non-current assets</b>		
	(a) Property, plant and equipment	0.38	0.37
	(b) Capital work-in -progress	-	-
	(c) Goodwill	-	-
	(c) other Intangible assets	-	-
	(d) Intangible assets under development	-	-
	(e) Investments in subsidiary, joint ventures and associate	-	-
	(f) Non- current Financial Assets	-	-
	(i) Non-current Investments	-	-
	(ii) Non-current Trade receivables	-	-
	(iii) Non-current Loans	-	-
	(iv) Other Non-current financial assests	-	-
	<b>Total non-current financial assets</b>	<b>0.38</b>	<b>0.37</b>
	(g) Defferred tax assets (net)	-	-
	(h) Other non-current assets	-	-
	<b>Total non-current assets</b>	<b>0.38</b>	<b>0.37</b>
2	<b>Current Assets</b>		
	(a) Inventories	-	0.98
	(b) Current financial assets	-	-
	(i) Current Investments	1,655.89	1,500.92
	(ii) Trade receivables	126.16	160.20
	(iii) Cash and cash equivalentents	4.52	9.04
	(iv) Bank Balance other than cash and cahs equivalentents	7.82	14.41
	(v) Current Loans	1,568.25	1,559.49
	(vi) Other corrent financial assets	17.53	-
	<b>Total current financial assets</b>	<b>3,380.17</b>	<b>3,245.04</b>
	(c) Current tax assets (net)	-	-
	(d) Other current financial assets	-	-
	<b>Total Current assets</b>	<b>3,380.17</b>	<b>3,245.04</b>
3	Non-current assets classified as held for sale Regulatory deferral account debit balance and related deferred tax Assets	-	-
	<b>Total Assets</b>	<b>3,380.55</b>	<b>3,245.41</b>



<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>EQUITY</b>		
	Equity attributable to owner of parent		
	(a) Equity share Capital	3,128.73	3,128.73
	(b) Other equity	-41.82	-44.51
	<b>Total Equity attributable to owner of parent</b>	<b>3,086.91</b>	<b>3,084.22</b>
	(c) Non controlling interest	-	-
	<b>Total Equity</b>	<b>3,086.91</b>	<b>3,084.22</b>
<b>2</b>	<b>LIABILITIES</b>		
	<b>Non-current liabilities</b>		
	(a) <b>Non-current financial liabilities</b>		
	(i) Borrowings	26.28	26.27
	(ii) Trade Payables	-	-
	(iii) Other non-current financial liabilities	-	-
	<b>Total non-current liabilities</b>	<b>26.28</b>	<b>26.27</b>
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	-	-
	(d) Deferred government grants	-	-
	(e) Other non-current liabilities	-	-
	<b>Total non-current liabilities</b>	<b>-</b>	<b>-</b>
<b>3</b>	<b>Current liabilities</b>		
	(a) <b>Current Financial liabilities</b>		
	(i) Borrowings	-	-
	(ii) Trade paybles	256.05	115.53
	(iii) Other current financial liabilities	-	-
	<b>Total current financial liabilities</b>	<b>256.05</b>	<b>115.53</b>
	(b) Other current liabilited	0.61	-
	(c) provisions	10.70	19.39
	(e) Current tax liabilities (Net)	-	-
	(f) Deferred government grants	-	-
	<b>Total current liabilities</b>	<b>11.31</b>	<b>19.39</b>
	Liabilities directly associated with assets in disposal group		
<b>4</b>	classified as held for sale	-	-
	Regulatory deferral account credit balance and related deferred		
<b>5</b>	tax liability	-	-
	<b>Total liabilities</b>	<b>293.64</b>	<b>161.19</b>
	<b>Total Equity and Liabilities</b>	<b>3,380.55</b>	<b>3,245.41</b>



# Symbiox Investment & Trading Co Ltd

7A, Rani Rashmoni Road  
Kolkata - 700 013  
Phone : 033-3251 5833  
CIN : L65993WB1979PLC032012  
Website : www.symbioxinvestment.com  
E-mail ID : symbioxinvestment100@gmail.com

Date: 30<sup>th</sup> May, 2019

To,  
Compliance Department  
Metropolitan Stock Exchange of India Limited  
Vibgyor Towers, 4th floor, Plot No C 62, G - Block  
Opp. Trident Hotel, Bandra Kurla Complex,  
Bandra (E),  
Mumbai - 400 098

To,  
The Bombay Stock Exchange Limited,  
PJ Towers, Dalal Street  
Mumbai- 400 001

To,  
The Calcutta Stock Exchange Limited  
7, Lyons Range,  
Kolkata- 700 001

Ref: SEIB Circular No. CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Sub: Declaration pursuant to Regulation 33(3)(d) of the Securities & Exchange Board of India  
(Listing Obligation and Disclosure Requirements) Regulations, 2015 ["LODR"].

Sir/ Madam,

In compliance with Regulation 33(3)(d) of LODR as amended by SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

We do and hereby confirm that the Auditors of the Company, M/s Poddar Agarwal & Co., and Chartered Accountants have expressed an unmodified opinion in their Audit Report on the Standalone Financial Statements of the Company for the year ended 31<sup>st</sup> March, 2019.

Thanking you

Yours faithfully

For Symbiox Investment & Trading Co Ltd

*Neha Pansari*  
Neha Pansari  
Company Secretary  
M no: A31763

